Market Overview

AmerisourceBergen Is 'The Pony To Ride' For Biosimilars

Share:
Related ABC
10 Biggest Price Target Changes For Tuesday
Benzinga's Top Upgrades, Downgrades For January 17, 2017
DGI For The DIY: 2016 Portfolio Review (Seeking Alpha)

Shares of AmerisourceBergen Corp. (NYSE: ABC) closed up more than 3.7 percent on Monday, after analysts at UBS upgraded the stock from Neutral to Buy. In a report rolled out Sunday, the firm assured that AmerisourceBergen may have the "greatest leverage to U.S. biosimilars (~$65 bil biologics in 5 yrs)."

After the U.S. Food and Drug Administration approved the first biosimilar drug in the U.S. market a week ago, UBS conducted a "deep dive" analysis into the biosimilar opportunity set for the next five years. The firm concluded that "among all of the companies in our [the firm's] pharma supply channel coverage (drug distributors, PBMs, retail drug chains and LTC pharmacies), ABC will likely have the greatest EPS leverage." As such, they believe AmerisourceBergen "is 'the pony to ride' to capture upside related to the estimated $65 bil in biologics that may face biosimilar competition during 2015-'19."

As a result of this change, the firm raised its EPS estimates for fiscal 2015 (from $4.64 to $4.68), 2016 (from $5.38 to $5.48) and 2017 (from $6.07 to $6.27), and boosted its price target from $102 to $118.

Latest Ratings for ABC

DateFirmActionFromTo
Jan 2017Leerink SwannUpgradesMarket PerformOutperform
Jan 2017Bank of AmericaUpgradesNeutralBuy
Jan 2017MizuhoDowngradesBuyNeutral

View More Analyst Ratings for ABC
View the Latest Analyst Ratings

Posted-In: UBSAnalyst Color Biotech Upgrades Health Care Price Target Analyst Ratings General

 

Related Articles (ABC)

View Comments and Join the Discussion!